BSR has published an updated life-course guideline for the prescription and monitoring of conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs). Find out more via our blog. Join guideline working group Chair, Louise Mercer, and group members James Galloway, Katie Bechman, Akhila Kavirayani and Alan Davidson, in a roundtable discussion hosted by Prof Ernest Choy, Editor in Chief of Rheumatology to find out what is included in the publication and what has changed since ...
All content for Talking Rheumatology is the property of British Society for Rheumatology and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
BSR has published an updated life-course guideline for the prescription and monitoring of conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs). Find out more via our blog. Join guideline working group Chair, Louise Mercer, and group members James Galloway, Katie Bechman, Akhila Kavirayani and Alan Davidson, in a roundtable discussion hosted by Prof Ernest Choy, Editor in Chief of Rheumatology to find out what is included in the publication and what has changed since ...
Ep 29. GUIDELINES - BSR axial spondyloarthritis guideline 2025
Talking Rheumatology
20 minutes
7 months ago
Ep 29. GUIDELINES - BSR axial spondyloarthritis guideline 2025
BSR has published an update to the axial spondyloarthritis guideline. It's almost 10 years since the last iteration of the guideline. Our understanding and awareness of the disease has increased enormously. We now have 10 different therapies licensed for advanced management of axial spondyloarthritis, which are broadly divided into three different classes: TNF inhibitors, IL17 and JAK inhibitors. Join guideline working group Co-Chairs, Karl Gaffney, and Steven Zhao, members William Greg...
Talking Rheumatology
BSR has published an updated life-course guideline for the prescription and monitoring of conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs). Find out more via our blog. Join guideline working group Chair, Louise Mercer, and group members James Galloway, Katie Bechman, Akhila Kavirayani and Alan Davidson, in a roundtable discussion hosted by Prof Ernest Choy, Editor in Chief of Rheumatology to find out what is included in the publication and what has changed since ...
